System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Thibaud Damy is an expert in Cardiology at Hôpitaux Universitaires Henri-Mondor (France). As of October 2026, ScienceLeadR ranks Thibaud Damy in the top 1% of experts worldwide for Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy and Transthyretin Cardiac Amyloidosis. Thibaud Damy has authored 553 publications, the most recent in 2026, and is an investigator in 36 clinical trials, 7 of them ongoing. SLR score: 2,440 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Thibaud Damy Hôpitaux Universitaires Henri-Mondor France
2 440 ScienceLeadR Reputation 2440

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Biochemistry - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Assistance Publique - Hôpitaux de Paris

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 553

Citations

Citations: 31 204 1st author: 73 Last author: 118 Unique author: 4

Main journals

Eur Heart J 52
Arch Cardiovasc Dis 46
Archives of cardiovascular diseases. Supplements 34
Eur J Heart Fail 33
Archives of Cardiovascular Diseases Supplements 29

Best Journals

Eur Heart J 24
N Engl J Med 9
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy.
PMID 42728504 — phenotype, prealbumin, signs and symptoms, aged, therapeutics, amyloid, cardiomyopathies, survival rate, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Cardiol Ther20260
Frailty is a mortality risk factor in tafamidis-treated patients with transthyretin cardiac amyloidosis.
PMID 42721369 — mortality, prealbumin, aged, amyloidosis, geriatric assessment, risk factors, frailty, transthyretin cardiac amyloidosis		Amyloid20260
Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
PMID 42693367 — mortality, prealbumin, sex characteristics, sex, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis, sex differences		Cardiol Ther20260
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
PMID 42663301 — prealbumin, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		N Engl J Med Top journal20260
Cardiovascular-Related Mortality and Hospitalizations in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: A Post Hoc Analysis of the Phase 3 ATTR-ACT and Long-Term Extension.
PMID 42658466 — mortality, hospitalization, incidence, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Cardiol Ther20260

Clinical Studies 36

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Study Chair: 1

By phase:

Phase 3 17
N/A 15
Phase 2 3
Phase 1 1

By status:

Completed 21
Active not recruiting 5
Terminated 4
Recruiting 3
Unknown 2
Not yet recruiting 1

By type:

Interventional 27
Observational 9

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 3
multicentricup10 24

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CLEOPATTRA A research study to look at the effects of treatment with a medicine called coramitug (NNC6019 0001) in people with heart failure due to ATTR amyloidosis
2024-518899-31-00 — heart failure, heart, prealbumin, amyloidosis, research, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Recruiting2025
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-518343-38-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis		Phase 3Active not recruiting2025
A study to determine if ALXN2220 is effective safe and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR CM)
2023-506669-70-00 — safety, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Active not recruiting2024
TRITON CM A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-519917-72-00 — safety, prealbumin, amyloidosis, therapeutics, cardiomyopathies, transthyretin amyloidosis		Phase 3Not yet recruiting2025
A Phase 2 Multicenter Study to Test the Effects of ALXN2220 on Markers of Disease Severity and the Safety of Re Treatment in Patients with Transthyretin Amyloid Cardiomyopathy
2025-520506-35-00 — safety, prealbumin, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 2Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS